Report Details:
15 Companies Covered
200 Pages
Autoimmune Disease Treatment Market Overview
The Autoimmune Disease Treatment Market size was valued at USD 18.23 Billion in 2024. The market is projected to grow from USD 19.51 Billion in 2025 to USD 38.42 Billion by 2035, registering a CAGR of 7.01% during the forecast 2025–2035.
An autoimmune disorder occurs when the body’s immune system is unable to differentiate between own cells and foreign cells, which causes the body to mistakenly attack normal cells. The most common autoimmune disease symptoms include abdominal pain, recurring fever, swollen glands, fatigue, and joint pain, swelling, and skin problems.
On the regional basis, the Americas autoimmune disease treatment market is segmented into two major regions North America and South America. The North American region holds a major share of the global autoimmune disease treatment market owing to the rising prevalence of autoimmune diseases, existing well-established healthcare system, and improving funding and reimbursement policies.
North America is the largest market for autoimmune disease treatments, holding approximately 45% of the global market share. Key growth drivers include a high prevalence of autoimmune diseases, advanced healthcare infrastructure, and significant investments in research and development.
Europe Autoimmune Disease Treatment Market accounted for 30% share in 2024, generating around USD 5.47 billion, making it the second-largest regional market. The region benefits from robust healthcare systems and a growing awareness of autoimmune diseases, driving demand for effective therapies.
Various other factors such as, increasing government assistance, rising prevalence of co-existing disorders, improving regulatory framework, increase in research and development expenditure, rising funding and reimbursement, and increasing adoption rate may contribute to the growth of the global connective tissue disease market.
South America is still a developing region in terms of the infrastructure and technology.
The global autoimmune disease treatment market is segmented on the basis of disease type, diagnosis, therapeutic products, and distribution channels.
Some of key the players in the global autoimmune disease treatment market are Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb Company, Thermo Fisher Scientific, and others.
